# NORTHWEST BIOTHERAPEUTICS INC (NWBO) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_f0bb147accd92b521386 · retrieved 2026-08-11T15:52:44.500Z

## Overview
Northwest Biotherapeutics is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers.

On July 29, 2026, Northwest Biotherapeutics entered into a $4.9 million convertible promissory note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP. The note has a 12-month term with no payments due until maturity, carries a 5% original issue discount with no interest, and is convertible at the holder's option at a small discount to the then-prevailing market price. The company also entered into a standby equity subscription agreement allowing it to require Yorkville to subscribe for up to $50 million of common shares at any time during a 24-month term at a small discount to market price, after the note is repaid or converted. Additionally, Yorkville acquired a warrant to purchase up to $2 million of shares at $0.205 per share.

## Terms
- Counterparty: YA II PN, Ltd. (Yorkville Advisors Global, LP) · Deal value: $4.9M · Consideration: cash · Price/share: $0.205

## Key dates
- Announced 2026-07-31

## Timeline
- 2026-07-31 · 8-K (0001104659-26-089293): 8-K - NORTHWEST BIOTHERAPEUTICS INC — *Northwest Biotherapeutics is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers.* On July 29, 2026, Northwest Biotherapeutics entered into a $4.9 million convertible promissory note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP. The note has a 12-month term with no payments due until maturity, carries a 5% original issue discount with no interest, and is convertible at the holder's option at a small discount to the then-prevailing market price. The company also entered into a standby equity subscription agreement allowing it to require Yorkville to subscribe for up to $50 million of common shares at any time during a 24-month term at a small discount to market price, after the note is repaid or converted. Additionally, Yorkville acquired a warrant to purchase up to $2 million of shares at $0.205 per share.
  https://www.sec.gov/Archives/edgar/data/1072379/0001104659-26-089293.txt

## Citations
- 0001104659-26-089293 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926089293